SUMMIT, NJ — Atlantic Health System Cancer Care at Overlook Medical Center is now offering a highly advanced technology that will enhance the ability of physicians to diagnose, stage and treat prostate cancer.
The UroNav Fusion Biopsy System fuses pre-biopsy magnetic resonance imaging (MRI) images of the prostate with ultrasound-guided 3-D images in real time, allowing for excellent imaging of the prostate and any abnormal changes (lesions) that may or may not be cancerous.
“Here at Atlantic Health System Cancer Care, we have strived to provide the latest technologies to benefit our patients,” said Dennis Lowenthal, MD, medical director, Carol G. Simon Cancer Center at Overlook Medical Center. “UroNav’s MRI/ultrasound fusion-guided biopsy is now the latest technology for prostate cancer diagnosis. The quality of imaging enables us to get the most accurate results, and to guide the most effective treatment plan if cancer is found. This is the next generation of prostate cancer detection.”
Prostate cancer is the second most common cancer in men after skin cancer. When caught early, it is highly treatable.
“Prostate specific antigen (PSA) testing and the digital rectal exam (DRE), the most common means of screening for prostate cancer, can be unreliable and can lead to many uncertainties,” said Dr. Lowenthal. “Trans-rectal ultrasound-guided (TRUS) biopsy, which is the current standard for prostate cancer detection when the PSA is elevated or something suspicious is found on DRE, may provide less optimal imaging of both the prostate and biopsy needle, and the needle may pass through tumor-free areas of the prostate, therefore missing the tumor. The UroNav system addresses both of these issues.”
The UroNav fusion biopsy system combines electromagnetic tracking and navigation, similar to a car’s GPS, with an onboard computer and a real-time imaging interface in one easy-to-use, mobile workstation.
A small, localized electromagnetic field is generated and used in conjunction with a navigation sensor mounted to the existing ultrasound transducer. The physician simply positions the navigation system above the patient and is ready to take advantage of UroNav’s simple, guided workflow. This workflow follows the same TRUS biopsy procedure urologists already use.
“Radiology data are easily and quickly transferred to UroNav for review and target identification,” said Terrence Lee, MD, a radiologist at Overlook Medical Center. “UroNav helps target suspicious lesions which can increase accuracy in diagnosing prostate cancer.”